1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,128 | 0,139 | 22:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| Do | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| Do | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 03.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.05. | Viva Biotech: From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery | 594 | PR Newswire | SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated... ► Artikel lesen | |
| 26.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 08.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 22.04. | VIVA BIOTECH (01873): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 07.04. | Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity from Discovery to Development and Manufacturing | 586 | PR Newswire | Delivering Continuity in a Changing LandscapeClients across the region view Viva Biotech not just as a service provider, but as a consistent, reliable partner and collaborator, an extension of their... ► Artikel lesen | |
| 30.03. | Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up | 377 | PR Newswire | CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading AdvantagesThroughout 2025, revenue from the Company's CRO business rose from RMB810.9 million... ► Artikel lesen | |
| 30.03. | Viva Biotech Holdings Full Year Profit Climbs | 2 | RTTNews | ||
| 30.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 18.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,271 | +0,22 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| NOVONESIS | 54,66 | +0,51 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 230,20 | +0,66 % | Genmab A/S: Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival | Company Announcement Topline results from Phase 3 EPCORE DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,090 | +2,51 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 258,00 | +4,88 % | BEONE MEDICINES Required to Pay Over RMB446M in Additional Income Tax and Late Fees | ||
| MUSTGROW BIOLOGICS | 0,228 | -3,39 % | SAP sucht den Boden, BYD greift an, MustGrow Biologics tankt frisches Geld! Kommt jetzt der Rebound?! | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Der Wind an den weltweiten Aktienmärkten weht derzeit spürbar rauer, es gibt teils heftige Bewegungen nach oben und nach unten. Gerade... ► Artikel lesen | |
| SINO BIOPHARM | 0,492 | +4,23 % | Dividendenbekanntmachungen (24.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AH REALTY TRUST INC US04208T1088 0,14 USD 0,1229 EUR AMBEV SA ADR US02319V1035 0,0091 USD 0,008 EUR ARLANDASTAD GROUP AB SE0016276851 1... ► Artikel lesen | |
| VERICEL | 39,600 | -2,46 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 3,550 | +8,56 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject... ► Artikel lesen | |
| FAETH THERAPEUTICS | 23,670 | +3,50 % | Baird initiates Faeth Therapeutics stock with outperform rating | ||
| ZAI LAB LTD ADR | 16,000 | +1,27 % | ZAI LAB (09688): NEXT DAY DISCLOSURE RETURN | ||
| BIOXCEL THERAPEUTICS | 1,240 | +8,77 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 9,596 | +4,06 % | REGENXBIO Inc.: REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone | New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026
ROCKVILLE, Md., June... ► Artikel lesen | |
| AKEBIA | 0,975 | -0,35 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| ZEVRA THERAPEUTICS | 12,350 | +3,78 % | Zevra Therapeutics Announces Publication of Positive MIPLYFFA Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +10,08 % bei einem Aktienkurs von 0,131 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.